Treatment with atorvastatin to the National Cholesterol Educational Program goal versus 'usual' care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study.
about
Interventions to improve adherence to lipid lowering medicationStatins and fibrates for preventing melanomaInterventions to improve adherence to lipid lowering medicationRelation of different measures of low-density lipoprotein cholesterol to risk of coronary artery disease and death in a meta-regression analysis of large-scale trials of statin therapyImpact of treatment with rosuvastatin and atorvastatin on cardiovascular outcomes: evidence from the Archimedes-simulated clinical trialsCardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An updateUnmet need in the hyperlipidaemia population with high risk of cardiovascular disease: a targeted literature review of observational studiesEffect of statins and aspirin alone and in combination on clinical outcome in dyslipidaemic patients with coronary heart disease. A subgroup analysis of the GREACE studyStatins in the treatment of chronic heart failure: a systematic reviewLack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapyEfficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trialsThe effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trialsAll cholesterol-lowering interventions are expected to reduce stroke: Confirmatory data from IMPROVE-IT.Dyslipidemia in primary care--prevalence, recognition, treatment and control: data from the German Metabolic and Cardiovascular Risk Project (GEMCAS).Rosuvastatin versus atorvastatin in achieving lipid goals in patients at high risk for cardiovascular disease in clinical practice: A randomized, open-label, parallel-group, multicenter study (DISCOVERY Alpha study)Does combination therapy with statins and fibrates prevent cardiovascular disease in diabetic patients with atherogenic mixed dyslipidemia?Reassessing the benefits of statins in the prevention of cardiovascular disease in diabetic patients--a systematic review and meta-analysis.Effectiveness of statins for secondary prevention in elderly patients after acute myocardial infarction: an evaluation of class effect.Sigmoidal maximal effect modeling of low-density lipoprotein cholesterol concentration and annual incidence of coronary heart disease events in secondary prevention trials.Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170,255 patients from 76 randomized trials.The exclusion of patients with chronic kidney disease from clinical trials in coronary artery diseaseChange in prevalence of chronic kidney disease in England over time: comparison of nationally representative cross-sectional surveys from 2003 to 2010.The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials.Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV.Interventions to improve adherence to lipid-lowering medication.Lack of therapeutic interchangeability of HMG-CoA reductase inhibitors.Statins for the prevention of stroke: a meta-analysis of randomized controlled trials.Microalbuminuria and hypertension with focus on type 1 and type 2 diabetes.Potential nontraditional applications of statins.Treatment options for patients with the metabolic syndrome.The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study.The many roles of statins in ischemic strokeNew lipid-lowering agents.Management of lipids in patients with diabetes.Cholesterol management and the reduction of cardiovascular risk.Bias in observational studies of prevalent users: lessons for comparative effectiveness research from a meta-analysis of statins.Baseline diabetes as a way to predict CV outcomes in a lipid-modifying trial: a meta-analysis of 330,376 patients from 47 landmark studies.Meta-analysis of large randomized controlled trials to evaluate the impact of statins on cardiovascular outcomesNon-high-density lipoprotein cholesterol: an alternate target for lipid-lowering therapy.The clinical benefit of implementing guidelines in cardiovascular disease prevention in real world settings.
P2860
Q24236817-F65BFB28-52D4-4E82-923A-6CBEDE065088Q24245521-688E3D3C-5171-4247-A7D3-C5BCCA4B2451Q24245739-2F8E1702-E9F9-4864-85D8-F37E37D80A0CQ24594496-B41C2732-75AF-4A00-9D1F-65E838EB2DEEQ26776293-08FB4E30-AFB1-4406-A96C-75785D23FAFDQ26997059-5361DAE5-232A-4FBC-9664-266B9A968155Q28072161-7C232CBB-BE6C-4788-848A-3CF4091FE597Q28174014-C672890B-60A0-4BC3-918C-C3F6F2FF00C1Q28200294-0D4D6EFE-6623-40E6-B9A9-06484CEFF864Q28732707-7CED59A6-AA09-4828-8B21-38FB512B3921Q29617910-02AAE8A4-93C6-409A-9048-4A9AB6B41109Q30914775-2087CC45-B59A-4301-AA66-90300E18B775Q31101617-AC28A6D0-4CDD-409C-B8B1-5BC61BBD904CQ33376862-C3904468-9CC9-48F2-84F7-0E1C27AE0CFEQ33737675-105567BE-9F95-4306-ABF2-6C68099376EDQ33776187-8F1B1C7F-F46A-4A69-ADC4-2E9114C97995Q33776201-D5AAC191-BACA-4B54-825D-EB1356A14131Q33938868-2FEF49C1-A2E1-4C49-BCD7-0E50D8B7F958Q34041102-62FE29F6-C1A3-4B91-ABF3-83CCB464A88AQ34142678-8AF19C74-0F47-4973-8702-7C98F10FCE5AQ34175429-83A2FAA5-E877-40BC-92A7-F348E9F5B53EQ34264752-C95DD1B6-2E12-4DAF-A1F1-1C0BAEADB483Q34274829-81C7FB04-B689-4707-901C-1F8CF991E539Q34299778-45386413-0EEB-4700-870C-E891E2E724F3Q34547763-7CDCA47C-AB87-4D81-844E-A3E9CA36893CQ35009456-C7BFF92C-5A23-4987-B1E5-92506F5218E4Q35124353-5071E339-1170-45A1-8C60-5A06F995B429Q35161366-2D83F2FD-3E88-4C98-AD88-A656E81CCA43Q35169445-AD93BAAA-D471-4925-AFD6-DE9B0B1D7E50Q35543392-150B94C6-E288-4170-AC20-8B83FAF097E3Q35587723-1AE5B868-EA25-42A5-8EA7-31C1094EF497Q35595431-CCA8EEC1-4780-4948-8463-6F55556C1CDBQ35602647-1FEF982E-7B1D-4684-8093-2AF46EB09A04Q35675490-CEF07B52-B710-44DF-A890-E8DBC617E312Q35686489-2B47AFDE-6C3C-42D6-8641-531CAF766598Q35734332-1CF37988-3562-4E62-9BD5-D250A773BEDFQ35809770-47A9280E-4E18-4A07-A460-AAD7C9D336B2Q35826088-B2D78946-C38D-43BC-8207-7B4CFBF9A080Q35834124-4DB57F73-A046-4DC8-B9EA-A5DE7CD12866Q35843906-52A9F1B2-66B8-47DB-BD11-CCC5E17F585F
P2860
Treatment with atorvastatin to the National Cholesterol Educational Program goal versus 'usual' care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Treatment with atorvastatin to ...... ase Evaluation (GREACE) study.
@en
Treatment with atorvastatin to ...... onary-heart-disease Evaluation
@nl
type
label
Treatment with atorvastatin to ...... ase Evaluation (GREACE) study.
@en
Treatment with atorvastatin to ...... onary-heart-disease Evaluation
@nl
prefLabel
Treatment with atorvastatin to ...... ase Evaluation (GREACE) study.
@en
Treatment with atorvastatin to ...... onary-heart-disease Evaluation
@nl
P2093
P1476
Treatment with atorvastatin to ...... ase Evaluation (GREACE) study.
@en
P2093
Athanasios A Papageorgiou
Athanasios G Kontopoulos
Athanasios N Symeonidis
Bodosakis R Mercouris
Dimokritos S Demitriadis
Elias O Basayannis
Valasia V Athyrou
P304
P356
10.1185/030079902125000787
P407
P577
2002-01-01T00:00:00Z